ClinicalTrialsFinder
RecruitingPhase 2NCT06046248

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease

Sponsor

Northside Hospital, Inc.

Enrollment

25 participants

Start Date

Jan 29, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Graft Versus Host Disease

Summary

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Belumosudil and a drug called Rituximab for people with chronic graft versus host disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBelumosudil

200mg PO QD x 24 cycles (28-day cycle)

DRUGRituximab

375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses

Locations(1)

Northside Hospital

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06046248

Related Trials

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT059227616 locations

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT059966275 locations

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT0711603133 locations

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT0712407841 locations